Difference between revisions of "Sacituzumab govitecan (Trodelvy)"
Jump to navigation
Jump to search
m |
|||
| Line 9: | Line 9: | ||
*4/22/2020: Granted accelerated approval for adult patients with metastatic [[Breast cancer, triple negative|triple-negative breast cancer]] who received at least two prior therapies for metastatic disease. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01631552 IMMU-132-01])'' | *4/22/2020: Granted accelerated approval for adult patients with metastatic [[Breast cancer, triple negative|triple-negative breast cancer]] who received at least two prior therapies for metastatic disease. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01631552 IMMU-132-01])'' | ||
*4/7/2021: Granted regular approval for patients with unresectable locally advanced or metastatic [[Breast cancer, triple negative|triple-negative breast cancer]] (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02574455 ASCENT])'' | *4/7/2021: Granted regular approval for patients with unresectable locally advanced or metastatic [[Breast cancer, triple negative|triple-negative breast cancer]] (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02574455 ASCENT])'' | ||
| − | *4/13/2021: Granted accelerated approval for patients with locally advanced or metastatic [[Bladder_cancer|urothelial cancer]] (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. ''(Based on | + | *4/13/2021: Granted accelerated approval for patients with locally advanced or metastatic [[Bladder_cancer|urothelial cancer]] (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. ''(Based on TROPHY-U-01)'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
Revision as of 02:43, 11 June 2022
Mechanism of action
From the NCI Drug Dictionary: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.
Diseases for which it is used
History of changes in FDA indication
- 4/22/2020: Granted accelerated approval for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. (Based on IMMU-132-01)
- 4/7/2021: Granted regular approval for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. (Based on ASCENT)
- 4/13/2021: Granted accelerated approval for patients with locally advanced or metastatic urothelial cancer (mUC) who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. (Based on TROPHY-U-01)
History of changes in EMA indication
- 11/22/2021: Initial marketing authorization as Trodelvy.
Also known as
- Code names: IMMU-132, RS7-SN38
- Generic name: sacituzumab govitecan-hziy
- Brand name: Trodelvy